This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MAKO Surgical Shareholder Alert: The Briscoe Law Firm And Powers Taylor, LLP Investigate Possible Breaches Of Fiduciary Duty By The Officers And Directors Of MAKO Surgical Corp.

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor, LLP announce that the firms are investigating legal claims against the officers and Board of Directors of MAKO Surgical Corp. (“MAKO”) (NASDAQ: MAKO) related to potential securities violations between January 1, 2012 and May 7, 2012 (the “Class Period”).

“Recent revelations about alleged improper business practices and procedures regarding key aspects of the company’s business and other misleading financial statements have prompted the firms to investigate possible breaches of fiduciary duties and other violations of state law by MAKO officers and directors. Based on our investigation, we are prepared to pursue litigation to preserve the company and the value of MAKO stock for all shareholders,” said shareholder rights attorney Willie Briscoe.

If you are an affected investor and you want to learn more about the lawsuit or join the action, contact Patrick Powers at Powers Taylor, LLP, toll free (877) 728-9607, via e-mail at patrick@powerstaylor.com, or Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 706-9314, or via email at WBriscoe@TheBriscoeLawFirm.com. There is no cost or fee to you.

In a recently filed federal class action complaint, MAKO and certain of its officers and directors were charged with violating the Securities Exchange Act of 1934. Specifically, the complaint alleges that defendants’ issued materially false and misleading statements during the Class Period because defendants knew that: (a) MAKO was poised to suffer a wider first quarter loss as it was experiencing higher costs and slower sales of its RIO systems; (b) utilization rates of MAKO’s RIO systems were dropping; (c) MAKO’s 2012 outlook provided at the start of the Class Period lacked a reasonable basis when made; and (d) based on the above, defendants lacked a reasonable basis for their positive statements about the Company or its outlook. As a result, it is claimed that MAKO traded at artificially high prices during the Class Period, and when defendants revealed MAKO’s true financial condition and future business prospects, the price of MAKO common stock fell more than 40% from its Class Period high.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs